Given the co-occurrence of mutant KRAS with high HIF-1α and high galectin-3 levels in pancreatic cancer, our results suggest an application of Hsp90 inhibitors in this cancer type. The gene discussed is HSP90AA1; the disease is pancreatic neoplasm.